Application of FeNO in the diagnostic and therapeutic algorithm of pediatric asthma: From chronic cough and wheeze to personalized management.

IF 2.1 4区 医学 Q3 ALLERGY
Allergologia et immunopathologia Pub Date : 2026-05-01 eCollection Date: 2026-01-01 DOI:10.15586/aei.v54i3.1576
Peter Kunč, Jaroslav Fábry, Peter Ferenc, Martina Neuschlová, Renata Péčová
{"title":"Application of FeNO in the diagnostic and therapeutic algorithm of pediatric asthma: From chronic cough and wheeze to personalized management.","authors":"Peter Kunč, Jaroslav Fábry, Peter Ferenc, Martina Neuschlová, Renata Péčová","doi":"10.15586/aei.v54i3.1576","DOIUrl":null,"url":null,"abstract":"<p><p>Bronchial asthma is the most common chronic respiratory disease in children. Treatment approaches should aim to achieve disease control, reduce limiting symptoms, and improve quality of life. The routine management of patients with asthma relies on the assessment of symptoms (including persistent cough and wheezing) and spirometry results However, these strategies do not consider the level of airway inflammation, which is a fundamental pathognomonic feature of the disease. The use of biomarkers is increasing in an effort to better understand individual asthma pathways (endotyping), offering the potential for personalized treatment with innovative biologics. Elevated levels of fractional exhaled nitric oxide (FeNO) are an indirect marker of T2 airway inflammation. FeNO is one of the few biomarkers that has been implemented in routine clinical practice because of its undeniable advantages, such as accessibility, noninvasiveness, simple implementation, and cost-effectiveness. However, the current scientific evidence in children is insufficient to recommend its universal use in the diagnosis and treatment of all patients. Considering its known limitations, FeNO can enhance therapeutic processes, particularly in children with severe asthma. High FeNO levels predict a good therapeutic response to corticosteroids and selected biologics (e.g., omalizumab and dupilumab) and indicate an increased risk of exacerbation. Similarly, measuring FeNO levels in children with recurrent wheezing can help determine the risk of future asthma development. Various factors contributing to FeNO value variability must be considered when interpreting the results. The lack of robust clinical studies is reflected in inconsistent guidelines from professional societies regarding the use of FeNO in managing childhood asthma. This review aims to evaluate the advantages, disadvantages, and potential applications of FeNO measurements in light of new findings in the field.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 3","pages":"206-221"},"PeriodicalIF":2.1000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v54i3.1576","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Bronchial asthma is the most common chronic respiratory disease in children. Treatment approaches should aim to achieve disease control, reduce limiting symptoms, and improve quality of life. The routine management of patients with asthma relies on the assessment of symptoms (including persistent cough and wheezing) and spirometry results However, these strategies do not consider the level of airway inflammation, which is a fundamental pathognomonic feature of the disease. The use of biomarkers is increasing in an effort to better understand individual asthma pathways (endotyping), offering the potential for personalized treatment with innovative biologics. Elevated levels of fractional exhaled nitric oxide (FeNO) are an indirect marker of T2 airway inflammation. FeNO is one of the few biomarkers that has been implemented in routine clinical practice because of its undeniable advantages, such as accessibility, noninvasiveness, simple implementation, and cost-effectiveness. However, the current scientific evidence in children is insufficient to recommend its universal use in the diagnosis and treatment of all patients. Considering its known limitations, FeNO can enhance therapeutic processes, particularly in children with severe asthma. High FeNO levels predict a good therapeutic response to corticosteroids and selected biologics (e.g., omalizumab and dupilumab) and indicate an increased risk of exacerbation. Similarly, measuring FeNO levels in children with recurrent wheezing can help determine the risk of future asthma development. Various factors contributing to FeNO value variability must be considered when interpreting the results. The lack of robust clinical studies is reflected in inconsistent guidelines from professional societies regarding the use of FeNO in managing childhood asthma. This review aims to evaluate the advantages, disadvantages, and potential applications of FeNO measurements in light of new findings in the field.

FeNO在儿童哮喘诊治算法中的应用:从慢性咳嗽、喘息到个性化治疗。
支气管哮喘是儿童最常见的慢性呼吸道疾病。治疗方法应以控制疾病、减轻局限性症状和提高生活质量为目标。哮喘患者的常规管理依赖于症状评估(包括持续咳嗽和喘息)和肺活量测定结果,然而,这些策略没有考虑气道炎症的水平,而气道炎症是该病的基本病理特征。生物标志物的使用正在增加,以更好地了解个体哮喘途径(内皮分型),为创新生物制剂的个性化治疗提供了潜力。呼出一氧化氮分数(FeNO)水平升高是T2气道炎症的间接标志。由于其不可否认的优势,如可及性、无创性、实施简单和成本效益,FeNO是少数已在常规临床实践中实施的生物标志物之一。然而,目前儿童的科学证据不足以推荐在所有患者的诊断和治疗中普遍使用它。考虑到其已知的局限性,FeNO可以增强治疗过程,特别是对患有严重哮喘的儿童。高FeNO水平预示皮质类固醇和选定的生物制剂(例如,奥玛珠单抗和杜匹单抗)有良好的治疗反应,并表明病情恶化的风险增加。同样,测量反复喘息儿童的FeNO水平可以帮助确定未来哮喘发展的风险。在解释结果时,必须考虑影响FeNO值变异性的各种因素。缺乏可靠的临床研究反映在专业协会关于使用芬诺治疗儿童哮喘的不一致的指南上。本文旨在根据该领域的新发现评估FeNO测量的优点,缺点和潜在的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
131
审稿时长
6-12 weeks
期刊介绍: Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书